Latest Commercialisation News

Zeotech Limited has successfully completed a two-year methane control program, developing a zeolite-based biofilter that reduces landfill methane emissions by more than 90%. The company is now preparing for on-site trials and commercial deployment.

Orthocell has secured regulatory approval to sell its nerve repair product Remplir™ in Hong Kong well ahead of schedule, expanding its footprint across key global markets. This milestone complements recent clearances in the US, Canada, and Asia, positioning the company for significant growth in a multi-billion-dollar market.

Nanoveu Limited has upsized its placement to $3.02 million, securing additional funding to fast-track the development and commercial rollout of its semiconductor, 3D visualisation, and solar coating technologies.

Sabre Resources has completed the sale of its Ninghan Gold Project to Capricorn Metals, receiving $1.85 million in initial consideration plus ongoing royalties and milestone payments.

FBR Limited has completed the final tranche of its $6.3 million placement, enabling significant cost reductions and operational consolidation that position the company for a more sustainable future.

Nanoveu Limited has completed the first tranche of a $2.7 million capital raise, issuing over 61 million shares to bolster its advanced semiconductor and materials science ventures. Additional placements to executives and the Chairman are planned, pending shareholder approval.

Wide Open Agriculture secures $2.6 million via placement and plans a $500,000 Share Purchase Plan to fast-track its expansion into China and boost global sales of its lupin protein products.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

Sparc Technologies is progressing its innovative green hydrogen pilot plant and graphene-based anti-corrosion trials, supported by a recent A$2.7 million capital raise to accelerate commercialisation and R&D.

Algorae Pharmaceuticals has partnered with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its oncology pipeline development.

Aurora Labs has reached a critical design freeze milestone under its Australian Defence Force contract, advancing its novel 3D-printed propulsion system towards testing and validation phases.

Sparc Technologies has launched a Share Purchase Plan offering eligible shareholders the chance to buy new shares at a 28.6% discount, aiming to raise up to $500,000 to fund key growth initiatives.